NDA 050779 · B Braun
Cefazolin and Dextrose
Cefazolin Sodium · Injection
Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jul 27, 2000
Approved uses
5
Original approval plus efficacy supplements
Registered trials
207
37 Phase 3, 20 recruiting
FAERS reports
3,023
2,872 serious, 362 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 10, 2025.
Cefazolin for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for: Treatment of the following infections caused by susceptible isolates of the designated microorganisms in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: ( 1 ) Respiratory tract infections ( 1.1 ) Urinary tract infections ( 1.2 ) Skin and skin structure infections ( 1.3 ) Biliary tract infections ( 1.4 ) Bone and joint infections ( 1.5 ) Genital infections ( 1.6 ) Septicemia ( 1.7 ) Endocarditis ( 1.8 ) Perioperative prophylaxis in adults and pediatric patients aged 10 to 17 years old for whom appropriate dosing with this formulation can be achieved ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection and Dextrose Injection and other antibacterial drugs, Cefazolin for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ). 1.1 Respiratory Tract Infections Cefazolin for Injection and Dextrose Injection is indicated for the treatment of respiratory tract infections due to Streptococcus pneumoniae, Staphylococcus aureus and Streptococcus pyogenes in adults and pediatric patients for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration ( 2.1 , 2.2 , 2.4 , 2.5 ) and Use in Specific Populations (8.4) ] . Limitations of Use Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection and Dextrose Injection is indicated for the eradication of streptococci from the nasopharynx; however, data establishing...
Mechanism: Cefazolin is an antibacterial drug [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 26, 2024 Supplement 34 · Efficacy LetterLabel
- Nov 23, 2020 Supplement 27 · Efficacy LabelLetter
- Sep 18, 2014 Supplement 23 · Efficacy · priority review Letter
- Jan 13, 2012 Supplement 18 · Efficacy LabelLetter
- Jul 27, 2000 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
4 products under this application
- CEFAZOLIN AND DEXTROSE · CEFAZOLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
- CEFAZOLIN AND DEXTROSE · CEFAZOLIN SODIUM EQ 500MG BASE/VIAL · INJECTABLE, INJECTION · Discontinued
- CEFAZOLIN AND DEXTROSE · CEFAZOLIN SODIUM EQ 3GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
- CEFAZOLIN AND DEXTROSE · CEFAZOLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefazolin" as an intervention, any sponsor and status, largest first.
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
VA Office of Research and DevelopmentFederal agency
NCT02216227 · 23,005 participants · Start Apr 1, 2014 · Primary completion Feb 28, 2021
Drug: Mupirocin; Chlorhexidine gluconate and 3 more · For: Surgical Site Infection
Sites: Miami, Florida; Iowa City, Iowa; Baltimore, Maryland · 11 sites in all
- Prevention of Arrhythmia Device Infection Trial (PADIT)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01628666 · 12,814 participants · Start Dec 2012 · Primary completion Sep 8, 2017
Drug: Incremental; Conventional · For: Arrhythmia
Sites: Hamilton, Canada
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes StudyPivotal-lookingRecruiting
Monash UniversityAcademic, hospital or other
NCT05447559 · 9,180 participants (planned) · Start Feb 7, 2023 · Primary completion Dec 2027
Drug: Cefazolin; Water for injection · For: Surgical Site Infection
Sites: Dallas, Texas; Sydney, Australia; Brisbane, Australia · 27 sites in all
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Prevention of Infections in Cardiac SurgeryPivotal-lookingTerminated
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT02285140 · 5,989 participants · Start Apr 2015 · Primary completion Mar 10, 2025
Drug: Cefazolin; Vancomycin · For: Thoracic Surgery; Antibiotic Prophylaxis
Sites: Hamilton, Canada; Toronto, Canada; Montreal, Canada · 4 sites in all
- Prevention of Infections in Cardiac Surgery (PICS) Prevena StudyPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03402945 · 4,107 participants · Start Mar 5, 2018 · Primary completion Apr 27, 2023
Drug: Cefazolin; Vancomycin · For: Surgical Site Infections
Sites: Hamilton, Canada; London, Canada
- Antibiotic Prophylaxis in Metabolic Bariatric SurgeryPivotal-lookingStatus unknown
General Committee of Teaching Hospitals and Institutes, EgyptGovernment (non-federal)
NCT06510452 · 3,352 participants (planned) · Start Oct 1, 2024 · Primary completion Dec 1, 2025
Drug: 2000 mg of Cefazolin; 500 mg of Metronidazole IV and 1 more · For: Antibiotic Reaction; Wound Infection Superficial; Wound Infection Deep and 2 more
Sites: Alexandria, Egypt; Amersfoort, Netherlands
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaphylactic shock270
- anaphylactic reaction164
- hypotension154
- pyrexia137
- rash131
- anaemia92
- erythema92
- nausea88
- off label use84
- pneumonia84
- urticaria84
- tachycardia83
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 29 |
| 2005 | 55 |
| 2006 | 44 |
| 2007 | 43 |
| 2008 | 53 |
| 2009 | 27 |
| 2010 | 50 |
| 2011 | 106 |
| 2012 | 192 |
| 2013 | 45 |
| 2014 | 56 |
| 2015 | 74 |
| 2016 | 117 |
| 2017 | 83 |
| 2018 | 121 |
| 2019 | 148 |
| 2020 | 148 |
| 2021 | 139 |
| 2022 | 296 |
| 2023 | 318 |
| 2024 | 357 |
| 2025 | 319 |
| 2026 | 203 |
Recalls
4 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Nov 21, 2013 · Class I · Terminated
Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.
Nov 21, 2013 · Class I · Terminated
Presence of Particulate Matter: B. Braun Medical Inc. is recalling several injectable products due to visible particulate matter found in reserve sample units.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Lee TC, Barina LA, Walls G, et al. · N Engl J Med 2026 · Clinical Trial, Phase IV, Comparative Study
- Cefazolin.
Quintiliani R, Nightingale CH · Ann Intern Med 1978 · Clinical Trial, Comparative Study
- Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.
Prosty C, Noutsios D, Lee TC, et al. · Clin Microbiol Infect 2025 · Systematic Review, Meta-Analysis
- Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty.
Peel TN, Astbury S, Cheng AC, et al. · N Engl J Med 2023 · Multicenter Study, Randomized Controlled Trial
- Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.
Burdet C, Saïdani N, Dupieux C, et al. · Lancet 2025 · Multicenter Study, Randomized Controlled Trial
- Antibiotic resistance rates in hypervirulent Klebsiella pneumoniae strains: A systematic review and meta-analysis.
Beig M, Aghamohammad S, Majidzadeh N, et al. · J Glob Antimicrob Resist 2024 · Meta-Analysis, Systematic Review
Sponsor: B Braun
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.